Key facts
- Cellspect’s last known valuation is $142.1M (May 2019).
- It has raised $22.6M; the latest was Later Stage VC in May 2025.
- Notable investors include Mitsubishi UFJ Capital, FASTAR, MCP Partners, Tokyo University of Science Investment Management, Aflac Ventures Japan — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Cellspect
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellspect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellspect
Developer of in-vitro diagnostic agents and medical devices designed to offer the prognosis of endometriosis progression. The company's devices develop analytical instruments and diagnostic agents related to point-of-care testing to make medical treatment more familiar and contribute to the improvement by making diagnosis results on the cloud, enabling patients to get prompt and appropriate consultation about endometriosis progression and cancer treatment.
- Sector
- Healthcare
- HQ
- Morioka, Japan
- Founded
- 2014
- Employees
- 50
- Website
- cellspect.com/
- Ownership
- Privately Held (backing)
Cellspect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellspect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellspect in its N-PORT filings yet. We sweep new filings monthly.